PMID- 21304293 OWN - NLM STAT- MEDLINE DCOM- 20110527 LR - 20110209 IS - 1473-5830 (Electronic) IS - 0954-6928 (Linking) VI - 22 IP - 1 DP - 2011 Mar TI - Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy. PG - 113-21 LID - 10.1097/01.mca.0000394697.74220.cd [doi] AB - Pharmacological adjuvant therapies to protect against procedure-related thrombotic complication are indispensable during percutaneous coronary intervention. In addition to antiplatelet therapy, use of anticoagulants to prevent acute thrombotic complication during percutaneous coronary intervention is essential. Besides unfractionated heparin (UFH), new anticoagulants have been developed and compared with UFH. Low-molecular weight heparins, direct thrombin inhibitors (e.g. bivalirudin), and recently developed agents such as fondaparinux (a factor Xa inhibitor) provide new alternatives to conventional UFH. FAU - Kim, Soo-Joong AU - Kim SJ AD - Department of Cardiology, College of Medicine, Kyung Hee University Medical Center, Seoul, Korea. FAU - Giugliano, Robert P AU - Giugliano RP FAU - Jang, Ik-Kyung AU - Jang IK LA - eng PT - Journal Article PT - Review PL - England TA - Coron Artery Dis JT - Coronary artery disease JID - 9011445 RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) SB - IM MH - *Angioplasty, Balloon, Coronary/adverse effects MH - Anticoagulants/adverse effects/*therapeutic use MH - Coronary Disease/*therapy MH - Fibrinolytic Agents/adverse effects/*therapeutic use MH - Hemorrhage/chemically induced MH - Humans MH - Thrombosis/blood/etiology/*prevention & control MH - Treatment Outcome EDAT- 2011/02/10 06:00 MHDA- 2011/05/28 06:00 CRDT- 2011/02/10 06:00 PHST- 2011/02/10 06:00 [entrez] PHST- 2011/02/10 06:00 [pubmed] PHST- 2011/05/28 06:00 [medline] AID - 00019501-201103000-00011 [pii] AID - 10.1097/01.mca.0000394697.74220.cd [doi] PST - ppublish SO - Coron Artery Dis. 2011 Mar;22(1):113-21. doi: 10.1097/01.mca.0000394697.74220.cd.